US 11,753,630 B2
Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene
Gary Owens, Durham, NC (US); Janel Lape, Wake Forest, NC (US); James Jefferson Smith, Morrisville, NC (US); John Morris, Raleigh, NC (US); Caitlin Turner, Durham, NC (US); Whitney Lewis, Oxford, NC (US); and Derek Jantz, Durham, NC (US)
Assigned to Precision BioSciences, Inc., Durham, NC (US)
Filed by Precision BioSciences, Inc., Durham, NC (US)
Filed on Sep. 13, 2022, as Appl. No. 17/931,896.
Application 17/931,896 is a continuation of application No. PCT/US2021/059146, filed on Nov. 12, 2021.
Claims priority of provisional application 63/233,664, filed on Aug. 16, 2021.
Claims priority of provisional application 63/113,131, filed on Nov. 12, 2020.
Prior Publication US 2023/0053176 A1, Feb. 16, 2023
Int. Cl. C12N 9/22 (2006.01); C12N 15/86 (2006.01)
CPC C12N 9/22 (2013.01) [C12N 15/86 (2013.01); C12N 2750/14143 (2013.01)] 11 Claims
 
1. A polynucleotide comprising a first nucleic acid sequence encoding a first engineered meganuclease and a second nucleic acid sequence encoding a second engineered meganuclease,
wherein said first engineered meganuclease binds and cleaves a nucleic acid at a site that comprises a recognition sequence consisting of the nucleic acid sequence of SEQ ID NO: 6 in a dystrophin gene and comprises the amino acid sequence of SEQ ID NO: 43,
and wherein said second engineered meganuclease binds and cleaves a nucleic acid at a site that comprises a recognition sequence consisting of the nucleic acid sequence of SEQ ID NO: 10 in said dystrophin gene, wherein said second engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 51.